A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of ADU-1604, an Anti-CTLA-4 Antibody, in Adults With Metastatic Melanoma
Phase of Trial: Phase I
Latest Information Update: 12 Dec 2018
At a glance
- Drugs ADU-1604 (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions; First in man
- Sponsors Aduro BioTech
- 24 Oct 2018 Status changed from not yet recruiting to recruiting.
- 14 Sep 2018 Status changed from planning to not yet recruiting.
- 20 Apr 2018 New trial record